<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04054817</url>
  </required_header>
  <id_info>
    <org_study_id>AC-2017-01</org_study_id>
    <nct_id>NCT04054817</nct_id>
  </id_info>
  <brief_title>ACRO Biocornea Clinical Trial in Taiwan</brief_title>
  <official_title>A Multi-center, Open-label, Single-arm Study Assess the Collagen Ophthalmic Matrix for Anterior Lamellar Keratoplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ACRO Biomedical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ACRO Biomedical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose:&#xD;
&#xD;
      Investigate the safety of ABCcolla Collagen Ophthalmic Matrix used for anterior lamellar&#xD;
      keratoplasty in patients suffering from fungal keratitis which cannot be treated with drugs.&#xD;
&#xD;
      Investigational medical device:&#xD;
&#xD;
        1. Product name: ABCcolla Collagen Ophthalmic Matrix&#xD;
&#xD;
        2. Manufacturer: ACRO Biomedical Co., Ltd.&#xD;
&#xD;
        3. Address of manufacturer: 3rd Floor, No.57, Luke 2nd Rd., Lujhu District, Kaohsiung City&#xD;
           82151, Taiwan (R.O.C.)&#xD;
&#xD;
        4. Indication: to replace human cornea in anterior lamellar keratoplasty&#xD;
&#xD;
        5. Classification: Class III&#xD;
&#xD;
      Study overview:&#xD;
&#xD;
      Each volunteer will be assigned a set of subject screening No. after signing the ICF. After&#xD;
      review of basic information and medical and drug history, screening of inclusion and&#xD;
      exclusion criteria and relevant assessment and record, the doctor will make the final&#xD;
      decision of whether to enroll the subject. Enrolled subjects will be assigned a subject&#xD;
      enrollment No. They will undergo keratoplasty using the investigational product and be&#xD;
      followed up for observation. Subjects are required to complete 9 visits (V2~V10) and will be&#xD;
      followed up for 24 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 11, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of irreversible graft dissociation or irreversible graft rejection within 6 months.</measure>
    <time_frame>After surgery, the patient will be assesed on day 3, 7, 14. After that patients will be evaluated at every 4 weeks for 24 weeks.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Fungal Keratitis</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lamellar keratoplasty-ABCcolla® Collagen Ophthalmic Matrix</intervention_name>
    <description>Lamellar keratoplasty was done by removing stromal layer, ABCcolla® Collagen Ophthalmic Matrix was sutured to the defective part of the cornea.</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>ACRO Biocornea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female from 20 to 80 years old&#xD;
&#xD;
          -  Subject who has been diagnosed as fungal keratitis by culture or dyeing or PCR or&#xD;
             confocal microscope&#xD;
&#xD;
          -  No response over a period of 2 weeks of Amphotericin B or Triazoles or Natamycin&#xD;
             treatment, and the depth or the size of ulcer increases or increased anterior chamber&#xD;
             inflammation&#xD;
&#xD;
          -  The keratitis affect corneal stroma depth to 1/2~2/3 and infiltrate &gt;2 mm diameter,&#xD;
             detected by OCT&#xD;
&#xD;
          -  Best corrected vision acuity &lt; 0.05&#xD;
&#xD;
          -  Subject who signs the informed consent form (ICF), and agree to complete the treatment&#xD;
             and follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Accepted keratoplasty&#xD;
&#xD;
          -  Has a corneal perforation and expect to have vision&#xD;
&#xD;
          -  Has severe dry eye&#xD;
&#xD;
          -  Experiences incomplete eyelid closure&#xD;
&#xD;
          -  Has liver function (ALT and AST) tests with score as two fold or greater as that of&#xD;
             the normal&#xD;
&#xD;
          -  Has renal function (Cr) levels greater than normal two folders&#xD;
&#xD;
          -  Has serum protein 10% low than normal&#xD;
&#xD;
          -  Has severe cardiovascular and cerebral vascular disease&#xD;
&#xD;
          -  Has diabetes&#xD;
&#xD;
          -  Has a tumor&#xD;
&#xD;
          -  Known to be allergic to collagen&#xD;
&#xD;
          -  Has a systemic collagen connective tissue disease&#xD;
&#xD;
          -  Has a constitution prone to severe allergic reactions&#xD;
&#xD;
          -  Uses anticoagulants 5 days before screening&#xD;
&#xD;
          -  Uses topical/oral/injectable NSAID 14 days before screening&#xD;
&#xD;
          -  Cannot accept investigated material due to religion or culture reason&#xD;
&#xD;
          -  Pregnant or breast-feeding women or childbearing-age women who plans to get pregnant&#xD;
&#xD;
          -  Participates in other drug or medical instrument clinical trials in the last 12 weeks&#xD;
&#xD;
          -  Not being considered suitable for this study by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Cheng Tai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tri-Service General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fan-Wei Tseng, Phd</last_name>
    <phone>886-7-6955569</phone>
    <phone_ext>232</phone_ext>
    <email>koli@acrobiomedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiun-Liang Hsu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiunn-Liang Chen, MD</last_name>
      <email>eyegogo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ko-Hua Chen, MD</last_name>
      <email>khchen@vghtpe.gov.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Cheng Tai, MD</last_name>
      <email>mingtai1966@yahoo.com.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Huang YH, Tseng FW, Chang WH, Peng IC, Hsieh DJ, Wu SW, Yeh ML. Preparation of acellular scaffold for corneal tissue engineering by supercritical carbon dioxide extraction technology. Acta Biomater. 2017 Aug;58:238-243. doi: 10.1016/j.actbio.2017.05.060. Epub 2017 Jun 1.</citation>
    <PMID>28579539</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

